Clinical Trial Detail

NCT ID NCT02807558
Title A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Syros Pharmaceuticals
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Azacitidine + Tamibarotene

Tamibarotene

Age Groups: adult senior

No variant requirements are available.